Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

Heat shock proteins in multiple myeloma

(2015) Lei Zhang et al.   Oncotarget

Inhibition of HSP90 molecular chaperones: moving into the clinic

(2013) Rocio Garcia-Carbonero et al.   LANCET ONCOLOGY

290 TAS-116, a Novel, Orally Bioavailable Highly Potent HSP90a/β Selective Inhibitor Demonstrates Favorable Tissue Distribution Properties Which Lead to Minimized Ocular Toxicity

(2012) Y. Kodama et al.   EUROPEAN JOURNAL OF CANCER

291 TAS-116, a Novel, Orally Bioavailable HSP90a/β Selective Inhibitor Demonstrates Highly Potent Antitumor Activity in Preclinical Models with a Favorable PK Profile

(2012) S. Ohkubo et al.   EUROPEAN JOURNAL OF CANCER

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

(2011) A. Rajan et al.   CLINICAL CANCER RESEARCH

Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma

(2011) T. Khong et al.   MOLECULAR CANCER THERAPEUTICS

Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells

(2010) Wen-Chuan Wu et al.   EXPERIMENTAL EYE RESEARCH

Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma

(2010) E L Davenport et al.   LEUKEMIA

Biologic sequelae of I B kinase (IKK) inhibition in multiple myeloma: therapeutic implications

(2009) T. Hideshima et al.   BLOOD

Bortezomib induces canonical nuclear factor- B activation in multiple myeloma cells

(2009) T. Hideshima et al.   BLOOD